Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Domainex
Domainex
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Design & Build
New biology centre opened by HM Lord-Lieutenant of Cambridgeshire
The new three-storey facility provides over 24,000 sqft for Domainex’s expanding biology/bioanalytical departments
Drug Delivery
Amphista Therapeutics partners with Domainex drug discovery portfolio
Domainex has experience in the field of TPD with expertise in designing, synthesising, and profiling targeted heterobifunctional protein degraders
Finance
Domainex acquires more than £1m of Waters equipment
The SQ detectors will enable Domainex to increase its capacity to analyse and purify compounds with higher molecular masses
Research & Development
Domainex opens dedicated facility at Unity Campus
“The investment into our new facility has allowed us to create a fully dedicated suite of labs to conduct our biology services”
Drug Delivery
Parkinson’s UK and Domainex collaborate on inflammation therapy
The organisations plan to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s
Research & Development
Queen’s University Belfast enters FLIP inhibitor collaboration
The university will work with Ipsen on the inhibitors, which have been supported by Domainex
Research & Development
Expanding the medicinal chemist’s toolbox
Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Subscribe now